🇺🇸 FDA
Patent

US 11389449

Treatment of metabolic syndrome with an sGC stimulator

granted A61KA61K31/506A61K45/06

Quick answer

US patent 11389449 (Treatment of metabolic syndrome with an sGC stimulator) held by Cyclerion Therapeutics, Inc. expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Cyclerion Therapeutics, Inc.
Grant date
Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/506, A61K45/06, A61K9/0053, A61P